Efemoral Medical Announces Issuance of 10th Patent
For Intravascular Stent in the Treatment of Peripheral Arterial Disease

Patents Now Issued Across All Major Geographies

LOS ALTOS, CA – December 13th, 2023 – Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the issuance of EP3522837, METHOD OF MANUFACTURING A RADIALLY RIGID AND LONGITUDINALLY FLEXIBLE MULTI-ELEMENT INTRAVASCULAR STENT. This represents Efemoral's 10th-issued patent across several different patent families.

The Efemoral Vascular Scaffold System (EVSS) with FlexStep Technology offers a new approach to treating peripheral arterial disease (PAD) by addressing the specific anatomical challenges and complex biomechanics of patients with athero-occlusive disease in the leg. Using inter-scaffold spaces, the patented FlexStep Technology combines flexibility with support to accommodate tortuosity and skeletal movement, while the balloon-expandable deployment system easily opens vessels and sustains healthy blood flow. The novel bioresorbable scaffold with long-term sirolimus elution aims to restore normal vessel diameter during the procedure, deliver therapeutic benefits across all lesion lengths and morphologies, prevent restenosis, and maintain patency while leaving no permanent implant behind.

"Human arteries have better short-term and long-term outcomes when treated with rigid balloon expandable stents," said Lewis B. Schwartz, MD, Co-Founder and CMO of Efemoral Medical. "However, you can't put a long rigid stent in the leg as it will break when you bend your knee. Therefore, most patients today are treated with self-expanding nitinol stents, which are not very strong, or balloons that do not address vessel recoil. The EVSS uses a unique design of alternating dissolvable scaffolds and spaces that, for the first time, allows the long arteries of the legs to be treated with the same, effective, balloon-expandable technology proven to be successful in other vascular beds."

PAD, also known as "poor circulation" or "hardening of the arteries," is a global plague. It affects approximately 200 million people worldwide,[1] including an estimated 20 million people in the United States.[2] Left untreated, PAD can lead to severe disability and extremity amputation. The effectiveness of current interventional treatment remains limited, with up to 50% of conventional endovascular procedures complicated by failure or recurrence within the first year.[3]

"The issuance of this 10th patent demonstrates Efemoral's strong commitment to protecting our intellectual property," said Christopher Haig, Co-Founder and CEO of Efemoral Medical. "We now have patents issued in all major markets, including the United States, Europe, China, India, and Japan. Furthermore, we have a pipeline of additional patent families and expect our patent portfolio to expand. We remain committed to creating value for our investors by building legal protections around our technology and advancing the science behind our device."

---

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377796/

[2] Yost, **The True Prevalence of PAD and the Economics of Major Amputation** Endovascular Today, May 2021

[3] https://www.researchgate.net/publication/260118801_Nitinol_Self-Expanding_Stents_vs_Balloon_Angioplasty_for_Very_Long_Femoropopliteal_Lesions

About Efemoral Medical, Inc.

Efemoral Medical, Inc. is developing next-generation bioresorbable solutions to treat patients with vascular disease. The company's initial product, the Efemoral Vascular Scaffold System (EVSS) with FlexStep Technology, is designed to offer a dedicated strategy for PAD interventions. The Efemoral Vascular Scaffold System (EVSS) is an OUS Investigational Device only.
To learn more, please visit efemoralmedical.com.

MEDIA CONTACT:
Katie Arnold
SPRIG Consulting LLC
katie@sprigconsulting.com

####